First Berlin Equity Research Raises Valneva SE Price Target to €6.80
I'm PortAI, I can summarize articles.
First Berlin Equity Research has raised Valneva SE's 12-month price target to €6.80, maintaining a "Buy" recommendation. Analyst Simon Scholes highlights the advanced clinical development of Valneva's Lyme disease vaccine, VLA15, in partnership with Pfizer. Phase 3 trial results are expected next year, with potential regulatory approval in 2026 and launch in 2027. The price target reflects increased expectations for VLA15, despite recent forecast adjustments for other products.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments